ArticleJournal of the American Heart Association2025
COVID-19 Vaccination and Cardiovascular Outcomes in Older Adults With Coronary Artery Disease and Heart Failure: Insights From a Large Propensity-Matched Cohort Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with coronary artery disease or heart failure (HF) face heightened COVID-19 and cardiovascular risk, yet the long-term cardiac effects of COVID-19 vaccination in this population remain uncertain.
methodsWe performed a retrospective, propensity-matched cohort study using the TriNetX US Collaborative Network (December 2020-December 2022). Adults with coronary artery disease or HF were matched 1:1, creating 74 236 vaccinated and 74 236 calendar-aligned unvaccinated patients. Outcomes included mortality, acute myocardial infarction, stroke, HF hospitalization, deep vein thrombosis/pulmonary embolism, atrial fibrillation hospitalization, myocarditis, pericarditis, percutaneous coronary intervention, and coronary artery bypass grafting at 1-year and 2-year follow-ups.
resultsVaccination was associated with a dose-dependent reduction in all-cause mortality. Landmark hazard ratios (HRs) remained favorable, 0.92 (95% CI, 0.89-0.95), 0.99 (95% CI, 0.96-1.02), and 0.72 (95% CI, 0.70-0.74), confirming robustness across time periods. Vaccination was also associated with fewer HF hospitalizations (2-year HR, 0.90 [95% CI, 0.87-0.94]) and lower revascularization rates (percutaneous coronary intervention HR, 0.87; coronary artery bypass grafting HR, 0.80), while showing no significant association with acute myocardial infarction, stroke, or venous thromboembolism. Although the study was underpowered to definitively assess rare safety events, a small increase in myocarditis was observed (2-year HR, 1.36), representing a potential safety signal that warrants further investigation; pericarditis was not significantly elevated.
conclusionsCOVID-19 vaccination was associated with a graded reduction in mortality that persisted after landmark adjustment, as well as lower rates of HF admissions and revascularizations. Findings support the use of complete vaccination, including boosters, as part of secondary prevention, pending confirmation in prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.